MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.400
-0.130
-3.68%
After Hours: 3.400 0 0.00% 16:37 09/20 EDT
OPEN
3.490
PREV CLOSE
3.530
HIGH
3.490
LOW
3.325
VOLUME
143.70K
TURNOVER
--
52 WEEK HIGH
17.95
52 WEEK LOW
2.920
MARKET CAP
123.48M
P/E (TTM)
-3.9650
1D
5D
1M
3M
1Y
5Y
Ampio Pharmaceuticals, 180 Life Sciences leads healthcare gainers; Nuwellis, Berkeley Lights among major losers
Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%, Berkeley Li...
Seekingalpha · 5d ago
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll
Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered market confidence and now many notable experts ar...
MENAFN · 6d ago
InnoCan Pharma receives strong buy recommendation: Here is why
Those who invested in InnoCan Pharma's (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) a year ago are up 273%.
MENAFN · 09/10 19:24
BRIEF-Brainstorm Cell Therapeutics Inc Says Preetam Shah, CFO Provided Co With Notice Of His Intent To Resign
reuters.com · 08/25 21:21
Brainstorm Cell Therapeutics Chief Financial Officer Preetam Shah Plans to Resign at August End
MT Newswires · 08/25 17:38
BRIEF-Brainstorm Cell Therapeutics Inc Files For Mixed Shelf Of Upto $200 Million - SEC Filing
reuters.com · 08/09 21:08
BCLI: Weighing Options for How Best to Advance NurOwn® in ALS…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT
Benzinga · 08/06 16:11
BrainStorm Cell Therapeutics EPS beats by $0.05
BrainStorm Cell Therapeutics (NASDAQ:BCLI): Q2 GAAP EPS of -$0.17 beats by $0.05. Cash, cash equivalents, and short-term bank deposits were ~$35M as of June 30, 2021, compared to ~$40.0Mon March
Seekingalpha · 08/05 11:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCLI stock price target is 11.50 with a high estimate of 12.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 76
Institutional Holdings: 5.73M
% Owned: 15.78%
Shares Outstanding: 36.32M
TypeInstitutionsShares
Increased
12
295.37K
New
9
892.69K
Decreased
25
2.94M
Sold Out
27
1.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Independent Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Vice Chairman/Independent Director
Irit Arbel
Chief Financial Officer
Alla Patlis
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Secretary/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Independent Director
Sankesh Abbhi
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
No Data
  • All
  • Financials
  • Insiders
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on development of cellular therapies for the treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD) and other neurodegenerative diseases. The Company offers its services through NurOwn platform. Its BrainStorm Cell Therapeutics Ltd. (Israeli Subsidiary) holds rights to commercialize the technology, NurOwn. Its NurOwn platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.